Vir Biotechnology, Inc.
http://www.vir.bio
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vir Biotechnology, Inc.
GSK Antibody Appears Effective In Older COVID-19 Patients
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Finance Watch: $2.2bn In New Funding Sources In February, So Far
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
Coronavirus Notebook: UK To Speed Up Trials Of New Drugs, Expands Use Of Tocilizumab
AstraZeneca and BioNTech are both boosting production of their vaccines in Europe, and the first batches of Comirnaty have arrived in Australia and New Zealand.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Humabs BioMed SA